Jasper Therapeutics is trading 11.9% higher at $0.65, primarily as biotechnology stocks rally on a stronger industry outlook and M&A optimism.
- XBI is up 2.55%, and major U.S. indexes are also higher.
- No clear company-specific September 17 catalyst was found.
- Jasper’s September 16 appointments of regulatory and clinical executives were reported alongside an inducement option grant; the move appears primarily sector-led.